<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1268</article-id><article-id pub-id-type="doi">10.25208/vdv1268</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НАУЧНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Epidemiology of psoriasis in the Russian Federation according to the patient registry</article-title><trans-title-group xml:lang="ru"><trans-title>Эпидемиология псориаза в Российской Федерации (по данным регистра)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7625-0503</contrib-id><contrib-id contrib-id-type="spin">8771-4990</contrib-id><name-alternatives><name xml:lang="en"><surname>Kubanov</surname><given-names>Alexey A.</given-names></name><name xml:lang="ru"><surname>Кубанов</surname><given-names>Алексей Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, член-корреспондент РАН</p></bio><email>alex@cnikvi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0662-2682</contrib-id><contrib-id contrib-id-type="spin">6372-2237</contrib-id><name-alternatives><name xml:lang="en"><surname>Bogdanova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Богданова</surname><given-names>Елена Витальевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>bogdanova@cnikvi.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center of Dermatovenereology and Cosmetology</institution></aff><aff><institution xml:lang="ru">Государственный научный центр дерматовенерологии и косметологии</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2022</year></pub-date><volume>98</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>33</fpage><lpage>41</lpage><history><date date-type="received" iso-8601-date="2021-08-18"><day>18</day><month>08</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-22"><day>22</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Kubanov A.A., Bogdanova E.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Кубанов А.А., Богданова Е.В.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Kubanov A.A., Bogdanova E.V.</copyright-holder><copyright-holder xml:lang="ru">Кубанов А.А., Богданова Е.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/1268">https://vestnikdv.ru/jour/article/view/1268</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Psoriasis is a chronic skin disorder that impairs patients’ health-related quality of life. It is associated with patients’ need in specialized medical care and with essential medical costs. Psoriasis may be the reason for temporary or permanent disability. Patient registries are important sources of epidemiological and clinical data on patients with psoriasis and medical care provided.</p> <p><bold>Aims.</bold> To describe demographic characteristics, characteristics of the disease, prevalence of concomitant and past diseases in adult (18 years and older) patients with moderate and severe psoriasis included in the patient registry of the Russian Society of Dermatovenereologists and Cosmetologists.</p> <p><bold>Materials and methods.</bold> The data of 3,268 patients with psoriasis aged 18 years and older were analyzed as of inclusion in the registry. Data lock point was June 3, 2021. Descriptive statistics methods were applied in data analysis.</p> <p><bold>Results.</bold> The mean (± SD) age of adult patients at inclusion in the registry was 46.1 ± 14.4 years. Male patients accounted for 60.5%. The mean age of onset of psoriasis is 31.1 ± 16.1 years. Most of the patients (89.5%) have psoriasis vulgaris. The mean body surface area at inclusion was 43.3% ± 24.7%. 28.9% of patients had psoriatic arthritis at inclusion in the registry.</p> <p>A high prevalence of cardiovascular diseases was revealed: arterial hypertension — 28.5%, coronary heart disease — 5.4%, myocardial infarction and acute cerebrovascular accident — 0.9% each.</p> <p>More than half of patients are pre-obese or obese according to the WHO body mass index classification. 2.2% of patients have impaired glucose tolerance, 6.7% of patients have type 2 diabetes mellitus. 3.8% of patients have diseases or dysfunction of the thyroid gland.</p> <p>The prevalence of diseases of the digestive system is high: any disease of the esophagus, stomach and duodenum was noted in 10.2% of patients, any disease of the liver, gallbladder, biliary tract and pancreas — in 11.8% of patients.</p> <p>The prevalence of viral hepatitis C among patients with psoriasis was 2.6%.</p> <p><bold>Conclusions.</bold> The prevalence of comorbidities is high among Russian patients with moderate and severe psoriasis.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Псориаз представляет собой хроническое заболевание кожи, оказывающее существенное влияние на качество жизни больных. Пациенты с псориазом нуждаются в оказании специализированной медицинской помощи, заболевание связано с высокими экономическими затратами, может быть причиной временной или стойкой утраты нетрудоспособности. Регистры пациентов представляют собой важные источники эпидемиологических и клинических данных о пациентах с псориазом и оказываемой им медицинской помощи.</p> <p><bold>Цель исследования.</bold> Описать демографические и клинические характеристики, частоту встречаемости сопутствующих и перенесенных заболеваний у взрослых (в возрасте 18 лет и старше) пациентов со среднетяжелыми и тяжелыми формами псориаза, включенных в регистр пациентов с псориазом Российского общества дерматовенерологов и косметологов (РОДВК).</p> <p><bold>Методы.</bold> Проведен расчет соответствующих показателей и анализ данных пациентов с псориазом в возрасте 18 лет и старше, включенных в регистр пациентов с псориазом РОДВК, по состоянию на момент включения в регистр. Данные для анализа получены по состоянию на 3 июня 2021 г. При анализе данных применены методы описательной статистики.</p> <p><bold>Результаты.</bold> В анализ были включены 3268 пациентов с псориазом в возрасте 18 лет и старше. Средний возраст взрослых пациентов на момент включения в регистр был равен 46,1 ± 14,4 года. Пациенты мужского пола составляли 60,5%. Средний возраст начала псориаза составляет 31,1 ± 16,1 года. Большей части (89,5%) пациентов установлен диагноз вульгарного псориаза. Средняя площадь поражения поверхности тела на момент включения составила 43,3% ± 24,7%. Диагноз псориатического артрита на момент включения в регистр был установлен 28,9% пациентов.</p> <p>Выявлена высокая частота встречаемости заболеваний сердечно-сосудистой системы: артериальной гипертензии / гипертонической болезни — 28,5%, ишемической болезни сердца — 5,4%, инфаркта миокарда и острого нарушения мозгового кровообращения — по 0,9%.</p> <p>Более половины пациентов имеют предожирение или ожирение по классификации ВОЗ в зависимости от индекса массы тела. Нарушение толерантности к глюкозе имеют 2,2% пациентов, сахарный диабет 2-го типа — 6,7% пациентов. Наличие заболевания или нарушения функции щитовидной железы констатировали у 3,8% пациентов.</p> <p>Высока распространенность заболеваний пищеварительной системы: какое-либо заболевание пищевода, желудка и двенадцатиперстной кишки отмечено у 10,2% пациентов, какое-либо заболевание печени, желчного пузыря, желчевыводящих путей и поджелудочной железы у 11,8% пациентов.</p> <p>Распространенность вирусного гепатита С среди пациентов с псориазом составила 2,6%.</p> <p><bold>Заключение.</bold> Российские пациенты с тяжелыми и среднетяжелыми формами псориаза имеют высокую распространенность сопутствующих заболеваний.</p></trans-abstract><kwd-group xml:lang="en"><kwd>registries</kwd><kwd>psoriasis</kwd><kwd>comorbidity</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>регистр пациентов</kwd><kwd>псориаз</kwd><kwd>коморбидность</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Кубанов А.А., Бакулев А.Л., Карамова А.Э., Притуло О.А., Аршинский М.И., Знаменская Л.Ф. и др. Клинические рекомендации. Псориаз. 2020 г. [Kubanov AA, Bakulev AL, Karamova AE, Pritulo OA, Arshinskij MI, Znamenskaja LF, et al. Klinicheskie rekomendacii. Psoriaz. 2020 (In Russ.)]. https://cr.minzdrav.gov.ru/</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Martínez-Ortega JM, Nogueras P, Muñoz-Negro JE, Gutiérrez-Rojas L, González-Domenech P, Gurpegui M. Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. J Psychosom Res. 2019;124:109780. doi: 10.1016/j.jpsychores.2019.109780</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kelly A, Ryan C. Genital Psoriasis: Impact on Quality of Life and Treatment Options. Am J Clin Dermatol. 2019;20(5):639–646. doi: 10.1007/s40257-019-00447-5</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Guo F, Yu Q, Liu Z, Zhang C, Li P, Xu Y, et al. Evaluation of life quality, anxiety, and depression in patients with skin diseases. Medicine (Baltimore). 2020;99(44):e22983. doi: 10.1097/MD.0000000000022983.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bulat V, Šitum M, Delaš Aždajić M, Lovrić I, Dediol I. Study on the Impact of Psoriasis on Quality of Life: Psychological, Social and Financial Implications. Psychiatr Danub. 2020;32(Suppl 4):553–561</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF. Stigmatization and Quality of Life in Patients with Psoriasis. Dermatol Ther (Heidelb). 2020;10(2):285–296. doi: 10.1007/s13555-020-00363-1</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Jankowiak B, Kowalewska B, Krajewska-Kułak E, Kowalczuk K, Khvorik DF. The Sense of Stigmatization in Patients with Plaque Psoriasis. Dermatology. 2021;237(4):611–617. doi: 10.1159/000510654</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>van Beugen S, van Middendorp H, Ferwerda M, Smit JV, Zeeuwen-Franssen ME, Kroft EB, et al. Predictors of perceived stigmatization in patients with psoriasis. Br J Dermatol. 2017;176(3):687–694. doi: 10.1111/bjd.14875</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, et al. Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. Clin Rheumatol. 2021;40(12):4933–4942. doi: 10.1007/s10067-021-05839-9</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, et al. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. J Med Econ. 2018;21(8):745–754. doi: 10.1080/13696998.2018.1472097</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017;20(9):982–990. doi: 10.1080/13696998.2017.1345749</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. Actas Dermosifiliogr. 2016;107(7):577–590. English, Spanish. doi: 10.1016/j.ad.2016.04.018</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):685–705. doi: 10.1586/14737167.2014.933671</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Assessing work-related productivity loss and indirect costs of psoriasis across six countries. Br J Dermatol. 2020;183(3):e65-e90. doi: 10.1111/bjd.19351</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Villacorta R, Teeple A, Lee S, Fakharzadeh S, Lucas J, McElligott S. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183(3):548–558. doi: 10.1111/bjd.18798</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Body mass index — BMI. https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, et al.; PSOLAR Steering Committee. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171(1):137–47. doi: 10.1111/bjd.13013</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Iskandar IY, Ashcroft DM, Warren RB, Yiu ZZ, McElhone K, Lunt M, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol. 2015;173(2):510–518. doi: 10.1111/bjd.13908</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kojanova M, Fialova J, Cetkovska P, Gkalpakiotis S, Jircikova J, Dolezal T, et al; BIOREP study group. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int J Dermatol. 2017;56(4):428–434. doi: 10.1111/ijd.13543</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Global report on psoriasis. World Health Organization. — 2016. ISBN 978 92 4 156518 9. https://www.who.int/publications/i/item/global-report-on-psoriasis</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One. 2013;8(5):e63619. doi: 10.1371/journal.pone.0063619</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol. 2017;18(4):583–590. doi: 10.1007/s40257-017-0274-0</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Bożek A, Reich A. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–856. doi: 10.17219/acem/69804</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. [Dedov II, Shestakova MV, Galstyan GR. Prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharnyy diabet. 2016;19(2):104–112 (In Russ.)] doi: 10.14341/DM2004116-17</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Duan X, Liu J, Mu Y, Liu T, Chen Y, Yu R, et al. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine (Baltimore). 2020;99(9):e19303. doi: 10.1097/MD.0000000000019303</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014–1024. doi: 10.1016/j.jaad.2013.06.053</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol. 2012;167(6):1345–1350. doi: 10.1111/bjd.12002</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062. doi: 10.1161/JAHA.113.000062</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. Arch Dermatol Res. 2017;309(3):225–228. doi: 10.1007/s00403-016-1712-1</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ungprasert P, Srivali N, Kittanamongkolchai W. Psoriasis and risk of incident atrial fibrillation: A systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2016;82(5):489–497. doi: 10.4103/0378-6323.186480</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Upala S, Shahnawaz A, Sanguankeo A. Psoriasis increases risk of new-onset atrial fibrillation: a systematic review and meta-analysis of prospective observational studies. J Dermatolog Treat. 2017;28(5):406–410. doi: 10.1080/09546634.2016.1255703</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(2):1405–1412. doi: 10.1016/j.dsx.2019.01.009</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Choudhary S, Pradhan D, Pandey A, Khan MK, Lall R, Ramesh V, et al. The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. Endocr Metab Immune Disord Drug Targets. 2020;20(5):703–717. doi: 10.2174/1871530319666191008170409</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(4):657–666.e8. doi: 10.1016/j.jaad.2017.04.1133</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Budu-Aggrey A, Brumpton B, Tyrrell J, Watkins S, Modalsli EH, Celis-Morales C, et al. Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Med. 2019;16(1):e1002739. doi: 10.1371/journal.pmed.1002739</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33(12):1163–1178. doi: 10.1007/s10654-018-0366-z</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656–662. doi: 10.1111/jdv.12847</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(12):1417–1423. doi: 10.1001/jamadermatol.2018.3631</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis. 2020;14(3):351–360. doi: 10.1093/ecco-jcc/jjz152</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Ungprasert P, Srivali N, Thongprayoon C. Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis. J Dermatolog Treat. 2016;27(4):316–321. doi: 10.3109/09546634.2015.1107180</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Li X, Kong L, Li F, Chen C, Xu R, Wang H, et al. Association between Psoriasis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. PLoS One. 2015;10(12):e0145221. doi: 10.1371/journal.pone.0145221</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277–1283. doi: 10.1007/s11255-018-1868-z</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2017;19(1):58. doi: 10.3390/ijms19010058</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Бакулев А.Л. Эволюция представлений о псориазе и терапевтических подходах по ведению пациентов. BCD-085 — первый отечественный генно-инженерный биологический препарат для лечения больных псориазом. Вестник дерматологии и венерологии. 2018;94(5):26–32. [Bakulev AL. Jevoljucija predstavlenij o psoriaze i terapevticheskih podhodah po vedeniju pacientov. BCD-085 — pervyj otechestvennyj genno-inzhenernyj biologicheskij preparat dlja lechenija bol'nyh psoriazom. Vestnik dermatologii i venerologii. 2018;94(5):26–32 (In Russ.)] doi: 10.25208/0042-4609-2018-94-5-26-32</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Egeberg A, Gisondi P, Carrascosa JM, Warren RB, Mrowietz U. The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(8):1695–1706. doi: 10.1111/jdv.16273</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Egeberg A. Psoriasis and comorbidities. Epidemiological studies. Dan Med J. 2016;63(2):B5201.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi: 10.1016/j.jaad.2016.07.064</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345–352. doi: 10.1016/j.jaad.2018.02.040</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Gliklich R, Dreyer N, Leavy M, eds. Registries for Evaluating Patient Outcomes: A User’s Guide. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD:Agency for Healthcare Research and Quality. April 2014. http://www.effectivehealthcare.ahrq.gov/registriesguide-3.cfm</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Brown ML, Gersh BJ, Holmes DR, Bailey KR and Sundt III TM. From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med. 2008;5(10):613–620. doi: 10.1038/ncpcardio1307</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology (Oxford). 2018;57(57 Suppl 7):vii54-vii58. doi: 10.1093/rheumatology/key109</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>O’Leary CP, Cavender MA. Emerging opportunities to harness real world data: An introduction to data sources, concepts and applications. Diabetes Obes Metab.2020;22(Suppl.3):3–12. doi: 10.1111/dom.13948</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>de la Torre Hernández JM, Edelman ER. From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research. Rev Esp Cardiol (Engl Ed). 2017;70(12):1121–1133. doi: 10.1016/j.rec.2017.07.008</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Egeberg A, Nast A. A critical eye on registry data in psoriasis. Br J Dermatol 2017;177:245–246. doi:10.1111/bjd.15309</mixed-citation></ref></ref-list></back></article>
